Fundraising Fox

Goldenrod Therapeutics, Inc.

Houston, US · Founded 2023 · Texas corporation · 1 known investors

Goldenrod Therapeutics develops brain-penetrant phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders, focusing on overcoming tolerability limitations of earlier PDE4 inhibitors to address neuroinflammation.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

Goldenrod Therapeutics, Inc. was founded in 2023 by Corey Hopkins.

CH
Corey HopkinsChair of the Department of Pharmaceutical Sciences and Director of the Center for Drug Design and Innovation at UNMC
DC
Dev ChatterjeeExecutive
LL
Leo Linbeck IVExecutive
MW
Mark WorschehExecutive

Board

AV
Atul VaradhacharyBoard director
LL
Leo Linbeck IIIBoard director
TB
Thomas BrenninkmeijerBoard director

Investors · 1

Fannin Goldenrod HoldingsreportedHouston

Reported raises · per SEC filings

Form D private placements

$3.2M disclosed across 1 round · 2026

▶$3.2MraisedJun 2026 · 2 investors · Biotechnology
Rule 506(b)
Goldenrod Therapeutics raises $6.5 million to test UNMC-created drug that could change modern medicine - Silicon Prairie Newssiliconprairienews.com · Jul 2026Goldenrod Therapeutics, Fannin Partners secures $6.5M for FA drug study - InnovationMaphouston.innovationmap.com · Jun 2026
Officers, directors & promoters on the filing
  • Dev ChatterjeeExecutive Officer
  • Leo Linbeck IVExecutive Officer
  • Mark WorschehExecutive Officer, Director
  • Atul VaradhacharyExecutive Officer, Director
  • Leo Linbeck IIIDirector
  • Thomas BrenninkmeijerDirector
Offering amount
$6.5M
Amount sold
$3.2M
Minimum investment
$100K
First sale
May 2026
Incorporated
Corporation, Texas, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Cloudinary3 shared keywordsCloudinary provides visual asset management and optimization tools for e-commerce teams, using AI-driven automation to enhance product images and videos for faster loading and improved conversion rates across sales channels.

Companies competing with Goldenrod Therapeutics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Goldenrod Therapeutics raises $6.5 million to test UNMC-created drug that could change modern medicine - Silicon Prairie Newssiliconprairienews.com · Jul 2026Goldenrod Therapeutics, Fannin Partners secures $6.5M for FA drug study - InnovationMaphouston.innovationmap.com · Jun 2026Goldenrod Therapeutics: $6.5 Million Seed Round Advances UNMC-Developed Brain Inflammation Therapy Toward Clinical Trialspulse2.com · Jun 2026Dr. Hopkins’ molecule moves closer to clinic | Newsroom | University of Nebraska Medical Centerunmc.edu · Jun 2026Hopkins molecule moves closer to clinic, startup raises $6.5 million - UNeMedunemed.com · Jun 2026Goldenrod Therapeutics Holds Initial Close of $6.5M Seed Fundingfinsmes.com · Jun 2026Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammationfinance.yahoo.com · Jun 2026

Frequently asked questions

What does Goldenrod Therapeutics, Inc. do?
Goldenrod Therapeutics develops brain-penetrant phosphodiesterase 4 inhibitors for neurological and neuropsychiatric disorders, focusing on overcoming tolerability limitations of earlier PDE4 inhibitors to address neuroinflammation.
Who founded Goldenrod Therapeutics, Inc.?
Goldenrod Therapeutics, Inc. was founded by Corey Hopkins in 2023.
Who are Goldenrod Therapeutics, Inc.'s investors?
Goldenrod Therapeutics, Inc.'s investors include Fannin Goldenrod Holdings.
How much funding has Goldenrod Therapeutics, Inc. raised?
Goldenrod Therapeutics, Inc. has disclosed $3.2M raised across 1 round.
Where is Goldenrod Therapeutics, Inc. headquartered?
Goldenrod Therapeutics, Inc. is headquartered in Houston, US.